Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study.

Cella D et al. Ann Hematol. 2018 Sep 4. doi: 10.1007/s00277-018-3469-4. [Epub ahead of print]

Bilateral Angle Closure Following the Infusion of a Monoclonal Antibody to Treat Relapsing Multiple Myeloma.

Lee AC et al. J Glaucoma. 2018 Sep. doi: 10.1097/IJG.0000000000000995.

Host genetic susceptibility to Clostridium difficile infections in patients undergoing autologous stem cell transplantation: a genome-wide association study.

Apewokin S et al. Support Care Cancer. 2018 Sep. doi: 10.1007/s00520-018-4173-6. [Epub 2018 Mar 28]

Incidence of Contrast-Induced Nephropathy in Patients with Multiple Myeloma Undergoing Contrast-Enhanced Procedures.

Crowley MP et al. Pathol Oncol Res. 2018 Oct. doi: 10.1007/s12253-017-0300-9. [Epub 2017 Sep 13]